{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:31:52Z","timestamp":1771716712206,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1280,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1124\/dmd.121.000366","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T17:40:12Z","timestamp":1621878012000},"page":"490-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of the Potential for Veverimer Drug-Drug Interactions"],"prefix":"10.1016","volume":"49","author":[{"given":"Dawn","family":"Parsell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Guttendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yick Sen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Tabakman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Stasiv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpesh","family":"Biyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Klaerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000366_bib1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2215\/CJN.08340812","article-title":"Effects of oral sodium bicarbonate in patients with CKD","volume":"8","author":"Abramowitz","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000366_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0272-6386(97)90045-7","article-title":"The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity","volume":"29","author":"Alpern","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/dmd.121.000366_bib3","unstructured":"Auryxia\u00ae [ferric citrate] (2014) Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Application Number: 205874Orig1s000, Clinical Pharmacology and Biopharmaceutics Review(s)."},{"key":"10.1124\/dmd.121.000366_bib4","series-title":"Medical Physiology","first-page":"895","article-title":"Gastric Function","author":"Binder","year":"2012"},{"key":"10.1124\/dmd.121.000366_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2215\/CJN.07300717","article-title":"Randomized, controlled trial of TRC101 to increase serum bicarbonate in patients with CKD","volume":"13","author":"Bushinsky","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000366_bib6","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000366_bib7","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1046\/j.1523-1755.2002.00656.x","article-title":"Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis","volume":"62","author":"Domrongkitchaiporn","year":"2002","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.121.000366_bib8","first-page":"121","article-title":"Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial","volume":"35","author":"Dubey","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/dmd.121.000366_bib9","unstructured":"Food and Drug Administration (FDA) (2014) Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs \u2014 General Considerations, Draft Guidance."},{"key":"10.1124\/dmd.121.000366_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02233563","article-title":"Ionic constituents and osmolality of gastric and small-intestinal fluids after eating","volume":"11","author":"Fordtran","year":"1966","journal-title":"Am J Dig Dis"},{"key":"10.1124\/dmd.121.000366_bib11","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1681\/ASN.2015040369","article-title":"Ketoanalogue-supplemented vegetarian very low\u2013protein diet and CKD progression","volume":"27","author":"Garneata","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000366_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2215\/CJN.02430312","article-title":"A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate","volume":"8","author":"Goraya","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000366_bib13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ki.2014.83","article-title":"Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate","volume":"86","author":"Goraya","year":"2014","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.121.000366_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ackd.2017.06.006","article-title":"Management of the metabolic acidosis of chronic kidney disease","volume":"24","author":"Goraya","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/dmd.121.000366_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/jpet.120.000190","article-title":"Mechanism of action of veverimer: A novel, orally administered, nonabsorbed, counterion-free, hydrochloric acid binder under development for the treatment of metabolic acidosis in chronic kidney disease","volume":"375","author":"Klaerner","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000366_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ki.2010.129","article-title":"Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy","volume":"78","author":"Mahajan","year":"2010","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.121.000366_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0016-5085(87)90837-7","article-title":"Simplified assessment of segmental colonic transit","volume":"92","author":"Metcalf","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.121.000366_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2009.519","article-title":"Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR","volume":"77","author":"Phisitkul","year":"2010","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.121.000366_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0250-474X.102545","article-title":"Assessment of drug-drug interactions among renal failure patients of nephrology ward in a South Indian tertiary care hospital","volume":"74","author":"Rama","year":"2012","journal-title":"Indian J Pharm Sci"},{"key":"10.1124\/dmd.121.000366_bib23","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/0016-5085(80)90925-7","article-title":"Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea","volume":"79","author":"Read","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.121.000366_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.ackd.2012.11.001","article-title":"Dietary acid load: a novel nutritional target in chronic kidney disease?","volume":"20","author":"Scialla","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/dmd.121.000366_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40266-020-00747-0","article-title":"Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy","volume":"37","author":"Sommer","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1124\/dmd.121.000366_bib26","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1002\/jps.22726","article-title":"Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions","volume":"100","author":"Thelen","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000366_bib27","unstructured":"Velphoro\u00ae [sucroferric oxyhydroxide] (2013) Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Application Number: 205109Orig1s000, Clinical Pharmacology and Biopharmaceutics Review(s)."},{"key":"10.1124\/dmd.121.000366_bib28","unstructured":"Veltassa\u00ae [patiromer] (2015) Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Application Number: 205739Orig1s000, Clinical Pharmacology and Biopharmaceutics Review(s)."},{"key":"10.1124\/dmd.121.000366_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1681\/ASN.2019070677","article-title":"Mechanisms of metabolic acidosis-induced kidney injury in chronic kidney disease","volume":"31","author":"Wesson","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.121.000366_bib30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(19)31388-1","article-title":"Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension","volume":"394","author":"Wesson","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000366_bib31","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(18)32562-5","article-title":"Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial","volume":"393","author":"Wesson","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000366_bib32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.2014.87","article-title":"pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development","volume":"96","author":"Zhang","year":"2014","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562409202X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562409202X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:53:55Z","timestamp":1740056035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562409202X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S009095562409202X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000366","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the Potential for Veverimer Drug-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}